Clariant AG (CLN) Earnings Call Transcript & Summary
November 3, 2026
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and welcome to the Clariant Third Quarter 9 Month Figure 2026 Conference Call and Live Webcast. Sandra here, your Chorus Call operator. This call is being recorded. <<operator_script>> Recording this conference for publication or broadcast is not permitted. Right now, I'm happy to pass things over to Andreas Schwarzwaelder, Head of Investor Relations. Sir, the floor is yours.
Andreas Schwarzwaelder
executiveThank you, Sandra, and good afternoon, ladies and gentlemen. I'm Andreas Schwarzwaelder, and I'm glad to have you with us on this Q3 conference call. With me today are Conrad Keijzer, Clariant's CEO, and Oliver Rittgen, Clariant's CFO. Conrad will open the call with an overview of how the third quarter developed, and after that Oliver will take us through the results for the business units. Conrad will then wrap up with the outlook for the full year 2026. A Q&A session will follow our presentation. Right now, all participants are in listen only mode. I'd like to remind everyone that forward-looking statements are included in the presentation, and these carry risks and uncertainties. Listeners and readers are therefore encouraged to refer to the disclaimer on Slide 2 of today's presentation. As a reminder, this conference call is being recorded. A replay and transcript of the call will be available in the Investor Relations section of the Clariant website. Let me now hand over to Conrad to begin the presentation.
Conrad Keijzer
executiveThanks, Andreas. For Q3 2026, Clariant posted robust local-currency sales growth. Sales came in at CHF 968 million, up 5.6% in local currency. If you set aside portfolio pruning, the local-currency increase was 6.7%. Care Chemicals and Adsorbents and Additives both grew strongly on favorable pricing and volumes, whereas Catalysts volumes continued to feel the effects of the Middle East conflict. Our EBITDA margin before exceptional items fell 230 basis points versus a year earlier, landing at 15.6%. Gains in Adsorbents and Additives were outweighed by corporate costs returning to normal after a prior-year one-off benefit, together with a less favorable mix and raw material-related effects. On a trailing 12-month basis, our free cash flow conversion rate rose 9 percentage points, reaching 48% versus 39% in the same period last year, thanks to better operating cash flow, disciplined capital spending and effective net working capital management. Full-year 2026 guidance is unchanged, with continued volatility and uncertainty tied to the Middle East conflict. Entering the final quarter, our order book is strong, especially in Catalysts, and we anticipate sustained business momentum in Care Chemicals and Additives. Fourth-quarter margins will be shaped by top line growth and a positive business mix.
Conrad Keijzer
executiveOur performance improvement programs will support this, along with ongoing active management of costs and pricing. Now I'll go into more detail on how sales performed during the third quarter. Pricing rose 5.7% and was positive in all 3 business units, lifted by strong value-based pricing actions that largely offset significant inflationary raw material prices. Volumes were down 0.1%, hit by the Middle East conflict and by our portfolio pruning measures. If you exclude portfolio pruning, group volumes were up 1%. Underlying volumes rose 2.1% in Care Chemicals and 1% in Adsorbents and Additives, whereas Catalyst volumes fell 1.9%. The reported revenue figure got a 1.3% benefit from currency tailwinds. Now on to profitability. EBITDA before exceptional items fell 6.5% year-on-year to CHF 151.5 million. That works out to a margin of 15.6%, versus 17.9% in the prior year. Let me give you some further detail on how the margin developed. The 230 basis point decline comes from 2 effects of broadly similar magnitude. First, a one-off year-on-year impact of roughly 100 basis points from the phasing of provisions in corporate costs. Second, an effect of roughly 100 basis points from volatile raw materials on the cost and valuation of inventory in Care Chemicals and Catalysts.
Conrad Keijzer
executiveOur performance improvement programs helped support margins throughout the group, especially in Adsorbents & Additives. Across the group in the third quarter, compared with the prior year, pricing largely compensated for raw material costs that were 12% higher, a 9% rise in energy, and logistics costs up 24%. Let me go into our savings programs in a bit more detail. The performance improvement programs we run are aimed at total run rate savings of CHF 100 million by 2027. By the end of 2026, we still expect CHF 90 million in run rate savings. Savings of CHF 10 million were achieved in the third quarter, which takes cumulative run rate savings achieved to CHF 79 million. Restructuring charges of CHF 6 million in the third quarter resulted from implementing the programs, bringing total program restructuring charges to CHF 99 million. Among the key measures announced in the third quarter is a further headcount reduction of around 70 positions, which raises the total announced reduction to around 700 positions. Targeted cost management initiatives continue to be implemented globally across the business units and corporate functions. With that, I will now hand over to Oliver, who will give further details on our business performance in the third quarter.
Oliver Rittgen
executiveThanks, Conrad, and good afternoon, everyone. We’ll now turn to how each business unit performed in the third quarter. In Care Chemicals, we posted strong underlying growth, led by the industrial businesses along with Personal and Home Care. Sales rose 8.7% in local currency on a basis that excludes our portfolio pruning measures, and 6.6% once those measures are included. Pricing climbed 6.5%, driven by higher formula-based prices and by our ongoing rollout of value-based pricing in response to clearly inflationary input costs. Volumes were up 0.1%, a figure that includes the effect of portfolio pruning, while underlying volumes rose 2.1%. Measured in Swiss francs, sales were up 8.4%, reflecting a 1.8% currency tailwind. The growth came from industrial applications, base chemicals, mining solutions and Personal and Home Care, helped by positive pricing and strong volume growth. Sales in Crop Solutions were flat, with volumes slightly lower. In this area, we anticipate a volume recovery in Q4. Sales in Oil Services fell because of the portfolio pruning effect tied to our exit in Argentina and because of the impact of the Middle East conflict. We saw an underlying decline at a low single-digit rate against a particularly strong quarter in the prior year. EBITDA before exceptional items came to CHF 93 million, which is a 0.3% decrease compared with the prior year.
Oliver Rittgen
executiveThat gave us an EBITDA margin before exceptional items of 17.5%, which is a decline of 150 basis points, and it reflects business mix as we saw an over proportional contribution from industrial businesses and the effects of volatile raw materials on costs and valuation of inventory. In Catalysts, sales rose 1.8% in local currency and 1.3% in Swiss francs. Pricing was up 3.7%, while volumes fell 1.9% versus the prior year period because of the significant impact of the conflict in the Middle East, with high-margin orders being delayed. Sales in Propylene more than doubled against a very low comparison base, while sales in specialties were flat. Sales in Ethylene decreased at a double-digit percentage rate, especially being affected by the shift of orders. Syngas and fuels decreased at a low single-digit rate, with good growth in fuel sales behind the investments in data centers, offset by softer demand in syngas. EBITDA before exceptional items decreased 29.4% to CHF 23.1 million, representing a corresponding margin of 13.3% compared to 19.1% in the prior year. Half of that decline was driven by volume impact from the conflict in the Middle East, resulting in lower operating leverage, along with a less favorable business mix.
Oliver Rittgen
executiveThe remaining half comes from a negative inventory valuation impact tied to softer precious metal prices. Ongoing order delays in the Middle East and elsewhere are still a factor, since a substantial number of force majeures and shutdowns persist across the industry. That said, we're observing normalization in Asia and fewer such cases among our direct customers. This leaves us with a solid order book and a favorable business mix, which gives us confidence in our expectation of a strong final quarter for the year. Turning to Adsorbents and Additives. We posted continued strong top line growth, driven by Additives. Sales rose 6.4% in local currency and 7.9% in Swiss francs, with pricing up 5.4% and volume up 1%. In the Adsorbents segment, sales grew modestly, as growth in renewable fuel applications in the United States more than offset weaker demand in industrial segments and edible oil purification in EMEA and APAC. In Additives, sales rose at a double-digit percentage rate, lifted by strong price and volume growth. In Polymer Solutions, demand remained strong, particularly in flame retardants and waxes, while Coatings and Adhesives gained from significant growth in passive fire protection. EBITDA before exceptional items rose 15.1% to CHF 48.9 million, and the corresponding margin climbed to 18.5% versus 17.4% in the prior year.
Oliver Rittgen
executiveThat 110 basis points of improvement came from favorable mix effects, active margin management, and contributions from our performance improvement programs. And with that said, I'll wrap up my remarks and turn things back over to Conrad.
Conrad Keijzer
executiveThanks, Oliver. I'll wrap up with what we're guiding for 2026. Across the whole year, our expectation remains that the market will stay difficult and volatile, with geopolitical uncertainty and risks persisting. The forecast from Oxford Economics now incorporates worldwide GDP growth of 2.6%, roughly matching the 2.5% they had in July, but projected expansion for the global chemical sector has been cut to negative 0.6% from 1% in July, reflecting a drawn-out Middle East conflict and the elevated energy prices tied to it. We anticipate contractions in the Middle East and Africa of minus 5.2%, in the U.S. of minus 1.5%, and in Europe of minus 0.2%, whereas chemical industry growth in China decelerates to 1.4% in 2026. The conflict still underway in the Middle East keeps weighing on orders in Catalyst and Middle East oil services and creates inflationary pressure across raw material, energy and logistics costs. To counter these effects, we keep applying our established value-based pricing, backed by active cost measures. Our 2026 guidance is unchanged: sales should come in around 2025 levels in local currency, and the EBITDA margin should be about 18% before exceptional items. That outlook rests on sustained strong business momentum in Care Chemicals and Additives, plus a firmer order book for the fourth quarter of 2026, especially in Catalysts.
Conrad Keijzer
executiveFor Catalysts, we're anticipating a quarter that matches last year, with better margins thanks to a favorable business mix. Our expectation is to reach free cash flow conversion above 45% in 2026. With that said, I'll hand the call back to Andreas.
Andreas Schwarzwaelder
executiveThanks, Conrad and Oliver. Ladies and gentlemen, the floor is now open for your questions. <<operator_script>> Thank you. Sandra, go ahead, please.
Operator
operator<<operator_script>> The first question is from Christian Faitz of Kepler Cheuvreux.
Christian Faitz
analystNice work on delivering fairly strong results during a tough stretch. I have two questions. First, regarding your guidance for the full year: what underpins the fairly steep Q4 improvement needed to hit that 18% full year EBITDA margin? By my math, roughly 21% EBITDA margins in Q4 would be needed to get there. Second, on the Catalysts side, I appreciate what you said about demand coming back in Asia. But what about the Middle East? Are there any encouraging signs that activity in the Middle East — or the Middle East conflict — is settling down? What are you hearing on the ground?
Conrad Keijzer
executiveYes, thanks Christian. So the two questions are somewhat connected, since what really gives us confidence in the guidance is Q4 and the way it lands. In October, we saw a solid beginning to the quarter across every business unit. Revenue at all business units is actually higher than a year earlier. In Catalysts especially, the order book looks very strong — not just on revenue, which we expect to finish in line with the prior year, itself quite strong, but on mix as well, which should actually be more favorable than the prior year. Perhaps specifically on Catalyst, to address your question: what we're seeing there in the Middle East is customers continuing to run shutdowns. Across the industry globally, we still have more than 100 force majeures in total. What we are seeing, though, is that the count is declining outside the Middle East. Customers aren't only impacted in the Middle East, since they can't ship finished product. Beyond the Middle East, a fair number of customers were also under force majeure owing to a lack of feedstock — mainly naphtha, but propane customers too, in China, Japan, and Korea.
Conrad Keijzer
executiveAnd at this point, we're actually seeing them successfully pull resources from other regions and get going again. So our order book reflects that. As a result, we're expecting Q4 to be a very strong quarter. And you're right that the EBITDA margin year to date stands at 17.1%. So it rests on a strong Q4, which we see in the order books and which we expect to bring us to roughly 18% EBITDA for the year.
Operator
operatorThea Badaro from BNP Paribas has the next question.
Thea Badaro
analystI've got two questions, if that's alright. First, regarding Care Chemicals: could you shed a little more light on the reasons margins came in so weak this quarter, aside from the inventory revaluation? Then the second one may be a bit sensitive — it's about the litigations. Could you give us more detail on what it would take for you to settle the case with Shell? Is that a scenario you might consider at some point?
Conrad Keijzer
executiveOn the claims, we can keep this brief. There's nothing new to report there. Shell and the Stichting Foundation have filed for an appeal, as anticipated. And yes, we remain very pleased with the unambiguous ruling the Amsterdam District Court issued in July, which backed our position. Turning to Care Chemicals — I'll let Oliver add a little more detail — you did see a really strong Q2, with margins up 300 basis points, though a positive inventory revaluation largely accounted for that. So in Q3 we actually saw the reverse: the cost of that inventory is elevated, and you now see that showing up in weaker margins. What matters is that we are securing our pricing. Sometimes there's a lag, mainly on formula pricing, but we're confident we are in fact recovering the full raw material increase in Care Chemicals as well — though a delay can occur at times. Oliver, I don't know if you wanted to comment on mix and other factors in Care Chemicals.
Oliver Rittgen
executiveYes, hi Thea. Perhaps I can build on what Conrad already said about the quarter-over-quarter figures and the inventory effect, and address the second element behind the margin performance in Care Chemicals. That second element is the mix we observed in Care Chemicals during the third quarter, looking at it by segment. Growth was very strong — and, I'd say, more than proportional — in the Industrial segment. That means industrial applications, the base chemicals. So in that respect, there's somewhat of a margin question on that side. We also saw growth in Personal and Home Care and in mining. But, as I mentioned, the industrial portion of that was more than proportional, and therefore it came with different margins. Combined with the inventory, that produced the margin slightly below the prior year.
Operator
operatorJames Hooper from Bernstein has the next question.
James Hooper
analystMy two questions, please. First one concerns the medium-term guidance. Congratulations on hitting the free cash flow target. But could you first help me bridge how you expect to reach the local currency revenue guide, and then next year's EBITDA margin — particularly on the local currency revenue guide, it appears a considerable deal is needed to get there, and the press have linked you to Ashland, for example. And then my second question, Conrad: I just want to follow up on remarks you made on TV this morning about unfair competition not only in China but also in the U.S. Could you give us a bit of context on any measures you see Europe implementing, and whether they'll be just antidumping or in the context of the quotas, please?
Conrad Keijzer
executiveYes, James, I’ll have Oliver go into more detail on the medium-term guidance and free cash flow. On the competition side, I can address that. So this morning the question was about Chinese competition in Europe and how the chemical industry views it. We actually had our Cefic board meeting just the other week in Portugal, where we gathered with all the industry representatives. And broadly speaking, the view is that global trade has always benefited Europe. Historically, 35% of chemical production in Europe was exported. So exports have been a growth driver for the European chemical industry. What clearly isn’t good is unfair competition. And the industry’s view, and Cefic’s view, is that when it comes to antidumping measures, the U.S. — sorry, the EU really needs to step that up. Selling below cost is obviously unfair competition. But if you look at general trade with China, it’s actually balanced in terms of duties. There’s anywhere between 0% and 5% duty on products going into China, but the reverse is the same actually.
Conrad Keijzer
executiveThe U.S. trade relationship is the less balanced one. For our goods entering the U.S., we still face a tariff of about 12.5%, while products coming from the U.S. into Europe pay no tariff at all. And as the gap in energy costs widens, gas prices in Europe are now actually 10 or 12 times more expensive than in the U.S. That is turning into a problem, and a considerable volume of polymers is now being imported into Europe. Yes, one important point to make for Clariant is that we have 68 factories around the world. So for us, tariffs do not have a significant impact on our results. By and large, we produce in a region for a region. Oliver, over to you on the medium term.
Oliver Rittgen
executiveYes. James, regarding the medium term — first, I agree with your take on cash performance. We're also happy with the above 45% we're guiding for this year. The medium-term guidance for cash performance was 40%. So the cash program we launched last year is really gaining traction. Discipline on working capital, discipline on CapEx, and how we execute are already delivering good results this year — partly at the end of last year too — and we're confident we'll maintain that execution next year as well. On sales and margin, medium-term guidance sits at 4% to 6%, but that assumes the market lands somewhere in the 2% to 4% range. Then on margin, we said 19% to 21%, versus roughly 18% where we'll finish this year; depending on the market outlook we adopt for next year, that's still how we view that medium-term range. But it's a little early to discuss guidance for next year on that point right now — we'll return to it in February.
James Hooper
analystAnd I apologize—just to add on, regarding the M&A question too, is that the path toward achieving that medium-term guidance?
Oliver Rittgen
executiveRegarding M&A, I don't have anything further to add beyond what we consistently state. Any M&A execution will be handled with discipline on our part. When opportunities are presented to us, we do review them. Maintaining our investment-grade rating is something we're committed to. And yes, that essentially covers what we can share about our M&A strategy.
Operator
operatorJulia Winckelmann from Bank of America has our next question.
Julia Winckelmann
analystLet me start with the Catalyst business. If I understood you right, you mentioned that sales are comparable to last year and the mix is improving. That means EBITDA ought to be higher than a year ago. From what I recall, last year came in at roughly CHF 60 million. Could you perhaps shed a little more light on which contracts are behind this sequential step-up? Is it a single large order, or several orders? Which product does it involve, and which region? Also, are the deliveries planned toward the start of the quarter or closer to its end? Put differently, is there any danger of slippage into 2027? My second question concerns CapEx. I believe you said you now anticipate it at the lower end of the range, whereas in the past it tended to sit above CHF 200 million. Are there particular projects or areas where you've chosen to trim CapEx? If yes, what's the reason? And would that also be the run rate for 2027 and beyond? Finally, a follow-up on M&A. I think you said before that your preference would be bolt-on acquisitions, and probably more in the consumer end market space.
Julia Winckelmann
analystAt what size would you call a deal a bolt-on? And does that remain the priority? Or might you look at bigger ones too?
Conrad Keijzer
executiveYes. All right. Thank you for your questions. We'll try to get to all 3. I believe Oliver can address CapEx. Yes, just to echo what Oliver said a moment ago regarding M&A. So let's be clear about this. Our company's strategy is, first and foremost, focused on organic growth and margin improvement. And on top of that, we actually have bolt-on acquisitions. So we would only pursue acquisitions if and when they strengthen our core segments, and we will be disciplined about it. We have a quality ambition, not a size ambition. And Oliver mentioned that for us, it's also very important to maintain our investment grade. So that, I think, is the framework for M&A, and there's no change there. As far as Catalysts and Q4 and the order book, yes, so overall we think catalyst will come in around last year in terms of revenue, but with a better mix. The order book is actually above last year. So that really gives us confidence heading into the fourth quarter. We saw a strong start in October. And in terms of mix, it's a positive mix. And what we mean by that is we see the segments with higher margins and particularly ethylene, but also propane to polypropylene, our CATOFIN catalysts, we see those orders in the books.
Conrad Keijzer
executiveAnd what that usually means is we ought to see margins a bit better than last year's.
Oliver Rittgen
executiveYes, Julia, regarding CapEx, we said the range was CHF 150 million to CHF 175 million, and also that we'd probably end this year toward the bottom of that range. I noted that we now have quite strong discipline in how we approach CapEx and spending. And of course, that's something we'll keep doing as we move forward. A level of roughly CHF 150 million is not unusual. That was the level we had last year as well. And you're correct, during 2020 to 2024, our CapEx rates were higher. But those were the major investments we made, such as in China in Daya Bay, to add capacity and to further reinforce the strategy Conrad also mentioned — producing and sourcing region for region. That was part of the strategy to substantially grow our presence in China, for example. But that capacity has now been built. We believe we have enough capacity for the growth ambition we hold. So that level of CHF 150 million to CHF 175 million is closer to a normalized CapEx level for us.
Operator
operatorChetan Udeshi from JP Morgan has the next question.
Chetan Udeshi
analystI’m simply trying to square what you said about a strong Q4 order book with the figures you’ve reported. It’s pretty rare for a company to miss and then claim Q4 actually looks great after missing Q3. And when I look at your volumes in Care Chemicals, they’re flat, while your volumes in additives are up maybe 1%. That doesn’t look like broad-based demand strength of the kind you seem to be describing. So you were saying you’ve in fact seen trends accelerate in Q4, and therefore you expect Q4 to be better. I’m somewhat confused by the Q4 comments compared with what you actually reported for Q3. And the second question — sorry to return to this M&A topic again, because I remember I put this question to you, Conrad, on the last conference call about the need for industry consolidation and the role Clariant will play. And if I’m not completely mistaken, you said at that time that the focus was on bolt-on acquisition. Since then, we’ve seen news flow that Clariant is actually looking to buy Ashland with the private equity. So it isn’t entirely clear how we should read what your intentions are?
Chetan Udeshi
analystAnd if there’s one in the pipeline, how would you even plan to finance a deal of that size?
Conrad Keijzer
executiveYes, Chetan, okay. Yes, starting with that strong fourth quarter. I think, yes, you brought up flat volumes in Care Chemicals. I think it's key to note that when you adjust for pruning, we're actually posting a 2% volume increase year-on-year in Care Chemicals. In Additives, you cited 1%. That figure is actually the combined growth of Additives and Adsorbents together. And what we're observing, especially in Adsorbents, is a pickup in business, particularly in the U.S., driven by the new renewable fuel incentives. Additives is already running well above a 1% CAGR, and we do see pockets there, particularly our flame retardants, where we're posting double-digit growth. So where we see volume headwinds in the business is actually in Catalysts, the minus 2%, which is entirely tied to the Middle East. And what we're also seeing in the Middle East is that, actually within the Middle East itself, there still are quite a number of force majeures. But outside the Middle East, we see that actually easing. So all of this is confirmed in our order book. Q4 is always seasonally strong for Catalysts. That's how the business works. People sort of run out their -- complete their CapEx budgets for the end of the year.
Conrad Keijzer
executiveA lot of the time, that falls under CapEx. This seasonality has always been there. And yes, so I think we're actually relatively optimistic. We see growth returning to the business, and not just -- because of pricing. No, we see underlying 2% growth in Care Chemicals. We see more than 1% growth in Additives and Adsorbents, and we see Catalyst starting a recovery. On the consolidation question that you had, or yes, you were more or less asking me to speculate on rumors. It's a good tradition in our industry that we don't comment on specific rumors or cases. But I will repeat that, yes, for us, it is important that we make acquisitions that strengthen the core segments in our company. And to your question on funding, yes, the investment grade for us is absolutely an important priority. So whatever we do has to stay within those parameters.
Operator
operatorOur next question is from Jaideep Pandya at On Field Investment Research.
Jaideep Pandya
analystFirst question, and again, apologies for asking, but it's about Catalyst. When you look ahead over the next 12 months to 18 months, I'm quite curious to understand the CATOFIN cycle and whether you have any other new products coming in the pipeline, both in terms of refill demand for CATOFIN and, I suppose, new plants, if any exist. So I'd just like to understand how the mix would evolve, given that CATOFIN was such a key driver of your mix in the previous peak, basically. The second question concerns — actually, it's the same question, but for 2 businesses. If you zoom into your Personal and Home Care, where you made the Lucas Meyer acquisition. And then if you look at the flame retardants business, where you added capacity in China, my understanding is that both of these are higher-margin businesses. And at least from the outside, they've been doing quite well. But the reported margin for the divisions hasn't really progressed much. So could you just give us some color on how these businesses are doing margin-wise? And if they are doing well, then what is the offsetting factor whereby margins have gone down and, therefore, the true color is not reflected?
Jaideep Pandya
analystThis final question is really connected to what Chetan was asking. If you look at Clariant's portfolio right now, what areas — it seems you want to direct more money toward Care Chemicals. So, to play devil's advocate, what strategic relevance do Adsorbents and Additives have? For instance, why wouldn't you consider a strategic review for that business if you're getting a good valuation that could potentially fund your plans in Care Chemicals, if that is the case?
Conrad Keijzer
executiveYes. Thank you, Jaideep. On that last item, I can say with confidence that if we were to conduct strategic reviews, those would be handled internally rather than necessarily on calls like these. And yes, when it comes to M&A, there isn't much I can add beyond what was said earlier. Regarding Catalyst, I'll offer a few remarks, and I believe Oliver can speak to the margin progression. Still, it's fair to say that Lucas Meyer and flame retardants are in fact delivering double-digit growth in the quarter. So those performances have left us very pleased indeed. On Catalyst, what matters, I think, is this: if you take a medium- or longer-term view, Catalyst has been disproportionately hit by the Middle East this year. So that is actually a significant part of our revenue. And we've been hit with force majeures within the Middle East, but also outside the Middle East. What I think you will see is that even in a continued turmoil scenario in the Middle East, you'll see a recovery of those plants that are on force majeure outside the Middle East. I think there's a second effect that we haven't talked about often, but that is that actually volumes that are out of the market from the Middle East are actually partly absorbed in the U.S.
Conrad Keijzer
executiveAnd in Europe too. There, you're seeing elevated operating rates in petrochemicals as well as base chemicals. The implication is that customers are pushing back their shutdowns, which means we're also seeing delays in the refill business. That's another thing that can't continue indefinitely. Eventually, yields start falling and companies will have to do a refill. So with those 3 elements in play, we aren't forecasting a rapid recovery in the Middle East given the turmoil right now. But we are seeing more refill business outside the Middle East. And I think that ought to show up in a recovery scenario for next year. Last, on new builds, what's encouraging is that we're seeing projects come in for the longer term. We were just awarded what is in fact the largest CATOFIN project to date, a 1.2 million tonnes CATOFIN line in China. Zheijang Petrochemicals has already placed that order with us for a new build that will land more toward the end of '27 or '28 in terms of when we book those sales. But you're actually seeing a wave of new builds ahead of the 2030 peak carbon year in China coming through, and that is genuinely very encouraging.
Conrad Keijzer
executiveOliver, could you say something about how margins are progressing?
Oliver Rittgen
executiveSure, Jaideep — what you're really asking about is how margins are developing across Care Chemicals overall, plus Additive and Adsorbents. I'll begin with Care Chemicals, and we've already touched on part of this. On the Personal Home Care side, margins make us very happy — both at Lucas Meyer and from the acquisition, as well as from our remaining businesses in that segment. Margin development was positive for the quarter as a whole, and likewise across the 9 months we're looking at. And the third quarter is especially shaped by mix, as we mentioned, correct? The industrial businesses carry an over-proportional share of sales, and along with that a larger share of margin contribution, compared with the more consumer-related businesses such as Personal Home Care and Crop Solutions. Crop Solutions came in flat for the quarter. But there, we anticipate Q4 bringing volume recovery and, with it, a margin increase in the Crop business, plus continued strong momentum in Personal Home Care — and along with that, continued strong momentum overall on the margin side for Care Chemicals. If you look at the 9 months for Care Chemicals, margins have risen by 30 basis points.
Oliver Rittgen
executiveSo that illustrates the trajectory and how we view it on a full-year basis as well. Then, turning to Additive and Adsorbents — you're right that Additives is doing really well on the growth side, in both volume and price. Margin is performing just as well. As you've seen, we're up 110 basis points in margin year-over-year. So that's a very positive margin performance overall for the quarter, also for Additives and Adsorbents. And for the full — for the first 9 months, we are up as well. And with that continued strong momentum we're seeing in Additives and also in parts of the Adsorbents businesses, we're also positive for Q4 to land a margin above the prior year, both for Care and for Additives and Adsorbents.
Jaideep Pandya
analystMay I — if I can fit in just one more question about Catalysts in the Middle East. Conrad, could you give us some detail on the product portfolio? Is it heavily weighted toward petrochemicals in that region? And does the margin profile of Clariant's Middle East Catalysts come in above the Catalysts average?
Conrad Keijzer
executiveYeah. So in the Middle East, about 15% of our Catalysts revenue comes from that region. It's a pretty substantial part of the business. It leans heavily toward petrochemicals and Syngas. So essentially that means CATOFIN and Syngas. And those, as you'd expect, are the higher-margin products within our portfolio. That's why you're seeing not just that revenue impact from the Middle East, but also the severe margin effect you saw.
Operator
operatorLisa De Neve of Morgan Stanley has the final question for today.
Lisa De Neve
analystI have several follow-ups. On the earlier question, you commented on your Crop Solutions segment and said you expect improved volumes in the fourth quarter. Could you shed a bit more light on what you're seeing in the underlying market for the fourth quarter, and perhaps also looking ahead to 2027, and how the competitive landscape looks on your customer side? Any thoughts there would be great. That's for Crop Protection. Second, on the A&A segment: you're seeing stronger U.S. Adsorbents demand, and you're seeing robust demand for flame retardants. How should we think about A&A margins in the fourth quarter? Should we simply assume they are significantly up year-on-year, or should we model them closer to the third quarter? Any thoughts on that would be great as well. And finally, a follow-up on the ethylene price cartel investigation -- litigation, sorry. Regarding the appeal by Shell and the Stichting Foundation, could you share how an appeal process like that works? Should we view it as a straightforward retrial of the case previously submitted, or will entirely different arguments be brought to the table here?
Lisa De Neve
analystWe’d also welcome any perspective you might have on that.
Conrad Keijzer
executiveYes. Okay, Lisa. So I'll begin with the last item, then offer a few remarks about Crop, and after that I believe Oliver can address the margin progression in A&A. Regarding litigation, how this would essentially unfold with the appeal is that hearings will come first. Those will be procedural hearings at some point next year. But what I think matters is really examining the first instance decision by the courts in the Netherlands in July, which was in fact an overwhelmingly positive outcome for Clariant and, I think, confirmed all of the statements that the company — that we as Clariant — made earlier in this — regarding this case. As for Crop Solutions and what we anticipate volume-wise and what we observe, I think, also relative to our competitors, I think Oliver already addressed it with an overall flat performance in Q3, which was slightly negative on volume and positive on price. We see — we are seeing higher volumes in Q4. That is more also actually competitor dynamics where we believe we are picking up some business and even our Q3 result, which was flat, if you compare that with some of what our competitors have announced so far, the flat overall performance versus prior year is actually not a bad performance at all in Crop as we speak.
Conrad Keijzer
executiveOliver, perhaps you could also offer a few remarks regarding how margins for A&A are expected to progress in Q4.
Oliver Rittgen
executiveLisa, that’s pretty much what I told Jaideep. I mean, for Q4, if you put it all together, we expect continued strong momentum in the additive business—both Coating and Adhesives—and also in Polymer Solutions, where performance has already been very strong year-to-date. So that momentum should carry on. Then, regarding renewable fuels in the U.S., we expect that to continue as well. With that, overall, when you’re modeling Q4, it’s fair to say margins will likely be at the prior-year level and higher.
Andreas Schwarzwaelder
executiveAndreas here. Many thanks. That brings us to the end of today's conference call. In due course, a transcript will be posted on the Clariant website, and the Investor Relations team is on hand for any additional questions you might have. Thanks again for being on the call, and goodbye.
Operator
operatorLadies and gentlemen, that brings the conference to a close. We appreciate your choice of Chorus Call, and we thank you for taking part in the conference. You can disconnect your lines at this time. Goodbye.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Clariant AG transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Clariant AG earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Clariant AG or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.